At the USZ, you can have the scientifically based Stockholm3 blood test, which significantly improves the early detection of aggressive prostate cancer, performed. It has been practiced in Sweden and Norway since 2017 and is now also available in other European countries.
Numerous scientific studies with a total of 75,000 participants have demonstrated the following benefits of the Stockholm3 test:
The Stockholm3 test
- detects more cases of aggressive prostate cancer,
- reduces the number of unnecessary prostate biopsies (tissue removal from the prostate),
- detects aggressive cancer even in men with low PSA (prostate specific antigen).
Who can do the Stockholm3 test?
The test is suitable for men between 45-75 years of age who have not had prostate cancer and whose PSA level is above 1.5 ng/ml.
Stockholm3 at USZ
If you are interested in a Stockholm3 blood test, sign up for a consultation now. The price of the Stockholm 3 test is CHF 502 and is invoiced directly to the patient by the laboratory, Institut für histologische und zytologische Diagnostik AG. The cost of the consultation and the PSA test is covered by your health insurance.
How much does Stockholm3 cost?
The price of the Stockholm 3 test is CHF 502 and is invoiced directly to the patient by the laboratory, Institut für histologische und zytologische Diagnostik AG.
All consultations around the test are chargeable and are usually covered by health insurance.
How does Stockholm3 work?
The Stockholm3 test is a blood test. This can be performed from a PSA level of 1.5 ng/ml.
Five different proteins and over 100 genetic biomarkers for the genetic risk profile are analyzed in the blood. The previous diagnostic standard, the PSA (prostate specific antigen), is also determined. These laboratory values, along with clinical data such as age, previous biopsies, and family history, are factored into a risk score for detecting aggressive early-stage prostate cancer.
From a PSA value of 1.5 ng/ml, we can send blood samples from our patients to Sweden, where laboratory analysis and bioinformatic evaluations are performed anonymously. The treating urologist receives a clear treatment recommendation after the analysis. This may include, for example, that the risk of aggressive prostate cancer is low and that further screening in 1-6 years is sufficient. Or it may recommend using further diagnostic procedures such as MRI (magnetic resonance imaging) or tissue sampling from the prostate (biopsy) to clarify whether cancer may be present. Together with the patient, all results are discussed and the further procedure is decided.
